Core progressive design

During this process of designing sequence changes, models were built and assessed to ensure that there were no obvious steric clashes and that the hydrophobic core was well packed. Furthermore, secondary structure prediction was also used to monitor the progress of change and to choose among different possible substitutions. The final sequence (see Table 17.3) contains 28 changes it had 50% identity to B1 and the similarity to Rop had increased from 5.4% identity to 41%. 

Its unique design suggests several accident scenarios that could not occur at other reactors. For example, failure to supply ECC to 1/16 of the core due to the failure of an ECC inlet valve. On the other hand, some phenomena of concern to other types of reactors seem impossible (e.g., core-concrete interactions). The list of phenomena for consideration came from previous studies, comments of an external review group and from literature review. From this, came the issues selected for the accident progression event tree (APET) according to uncertainty and point estimates. 

As we develop alternative polyurethanes and composites, we must be aware that an efficient system of quality vahdation must be developed, concurrent with progress to meet design requirements. While many of the tests described above will constitute the core of the validation procedure, additional tests are needed to fully describe the functions of the materials. 

The main can format for the European soft drinks market is the 330 ml size, made either from aluminium or steel a 250 ml size is also used. In US markets, the 12 and 16 oz sizes dominate. The core diameter is 206 for both soft drinks and beers, but in the last couple of years the market has progressively changed to the 202 diameter. (The designation 206 means a diameter of 2 " and 202 means a diameter of 2 ".) The core diameter is not the can body diameter but the neck plug diameter (see Figure 9.4 for an explanation of the terms used for can dimensions). These diameters have been metricated to a nominal 57 and 52 mm for 206 and 202, respectively. The purpose of reducing the neck diameter was to reduce the size of the can s end, thereby saving around 17-20% on the amount of metal... 

Because mutant CFTR is the core defect in CF, it is expected that pharmacological agents designed to increase CFTR function will prevent or slow disease progression (Fig. 1). There are two pharmacological approaches to increase mutant CFTR function. The first is to increase the cell surface density of mutant CFTR. This class of compounds is known as CFTR correctors (Fig. 2B). The second approach is to increase the open probability of mutant CFTR at the cell surface. This class of compounds is known as CFTR potentiators (Fig. 2B). Depending on the molecular consequence of the mutation... 

---